Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Shalabh K. Gupta
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 21
- Beta
- 1.78
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 0.10
Financials
Revenue
$0.00-100.0%Net Income
$-1.72MEBITDA
$-1.57MFree Cash Flow
$-7.60MEPS (diluted)
$-0.06Shares Outstanding (diluted)
26.92M+3288.7%Operating Expenses
$10.14MCash & Debt
$61.42MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-26.55M | $-1.67 |
| 2024 | $0.00 | $-36.73M | $-5.65 |
| 2023 | $675.0K | $-30.54M | $-12.80 |
| 2022 | $951.0K | $-18.06M | $-11.99 |
| 2021 | $0.00 | $-10.02M | $-6.68 |
| 2020 | $0.00 | $-2.51M | $-1.48 |
| 2019 | $0.00 | $-2.30M | $-1.42 |
| 2018 | $0.00 | $-1.12M | $-0.73 |
Valuation
UNCYhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
73+22.22%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·7d ago·Negative
…Application for Oxylanthanum Carbonate MOUNTAIN VIEW, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company's investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (…
View source ↗ - Newsprnewswire.com·7d ago·Negative
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit NEW YORK, Sept. 28, 2026 /PRNewswire/ -- Why: New York, N.Y.
View source ↗ - Newsprnewswire.com·26d ago·Negative
Unicycive Therapeutics, Inc. (UNCY) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit LOS ANGELES, Sept. 9, 2026 /PRNewswire/ -- The Law Offices of Frank R.
View source ↗ - Newsbusinesswire.com·29d ago·Neutral
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCY LOS ANGELES--(BUSINESS WIRE)---- $UNCY--Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – UNCY.
View source ↗ - Newsbusinesswire.com·30d ago·Negative
UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES--(BUSINESS WIRE)---- $UNCY--UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law.
View source ↗ - Newsglobenewswire.com·55d ago·Negative
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update - Company expects to resubmit New Drug Application (NDA) for oxylanthanum carbonate (OLC) assuming completion of successful inspection of third-party manufacturing vendor
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.33 per share
Typical surprise +25.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.06 vs $-0.47beat
- Tue, May 12$-0.54 vs $-0.55beat
- Mon, Mar 30$-0.82 vs $-0.46miss
- Wed, Nov 12$-0.33 vs $-0.59beat
- Thu, Aug 14$-0.52 vs $-0.70beat
- Wed, May 14$-0.50 vs $-0.67beat
Estimates and results for UNCY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by UNCY officers and directors.
- Bought
- $12k
- Sold
- —
1 trade
0 trades
- Schiller Brigittebought
92 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in UNCY.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.